Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03107078
Other study ID # ThirdAffiliatedHospitalOfSMU
Secondary ID
Status Recruiting
Phase Phase 4
First received March 8, 2017
Last updated April 16, 2017
Start date October 1, 2016
Est. completion date October 1, 2021

Study information

Verified date April 2017
Source The Third Affiliated Hospital of Southern Medical University
Contact Jie Shen, Doctor
Phone 13808893818
Email shenjiedr@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

For patients with active moderate-to-severe thyroid associated ophthalmopathy (TAO), the Intravenous Glucocorticoids (GCs) is the recommended therapy. However, the efficacy of GCs is not satisfied. Investigators established a novel classification of TAO for the first time to assess more precisely for better personal treatment.


Description:

TAO is one of most common extra thyroid manifestation of dysfunctional thyroid disease. Since the morbidity of TAO has been increasing rapidly, Investigators' team is intended to verify the feasibility of the new type of classification system established by the related parameters of orbital MRI scan. Based on classification, investigators compare the efficacy of two GCs therapy. According to MRI,investigators measure the optimal T2 signal intensity ratio (SIR) for the treatment of TAO, which may help to find a better treatment time for therapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date October 1, 2021
Est. primary completion date October 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. The diagnostic standard of TAO is according to Bartley's criteria.

2. Patients with active moderate-to-severe TAO based on 2016 EUGOGO guidelines.

3. CAS=3/7.

4. None of the patients received any glucocorticoids therapy or orbital radiotherapy in the previous 3 months.

Exclusion Criteria:

1. NOSPECS is 0 or 1.Only signs,no symptoms.Signs include:reduced blink(Stellwag symptoms),two reduced cohesion(Mobius levy),moving slowly on the eyelids(Von Graefe sign),to the point of view,the forehead wrinkled skin should not(Joffroyv levy).

2. Suffering from other eye diseases or wearing contact lenses.

3. Suffering from other autoimmune diseases.

4. Acute and chronic infectious diseases.

5. Diabetic retinopathy or hypertensive fundus lesions.

6. Patients received orbital decompression or other orbital surgery.

7. Suffering from eye trauma or ocular surface disease.

8. Special occupants, and the working environment has obvious air pollution etc.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Glucocorticoids
Intravenous Glucocorticoids (GCs)

Locations

Country Name City State
China the Third Affiliated Hospital of Southern Medical University Guangzhou Guangdong

Sponsors (4)

Lead Sponsor Collaborator
Jie Shen Huadu District People's Hospital of Guangzhou, The Fifth Affiliated Hospital of Southern Medical University, Zhujiang Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients defined as Response for the Glucocorticoids Treatment based on the 7 parameters of eye assessment "Response" was defined as at least three of the following outcome measures:
reduction in lid width by at least 3 mm;
reduction in any of the class 2 NOSPECS signs by at least two grades;
reduction in proptosis by at least 2 mm;
reduction in intraocular pressure by at least 2 mm Hg;
improvement in CAS by at least two points;
improvement in diplopia (disappearance or degrade in degree);
improvement in visual acuity by 1 Snellen line.
2years
Primary Number of patients defined as Deterioration for the Glucocorticoids Treatment based on the 7 parameters of eye assessment "Deterioration" of each parameter was defined as follows:
increase in lid width by at least 3 mm;
increase in any of the class 2 NOSPECS signs by at least two grades;
increase in proptosis by at least 2 mm;
increase in intraocular pressure by at least 2 mm Hg;
increase in CAS by at least two points;
increase in diplopia (new onset or upgrade in degree);
decrease in visual acuity by 1 Snellen line.
2years
Primary Number of patients defined as Unchange for the Glucocorticoids Treatment based on the 7 parameters of eye assessment "Unchanged" was defined as no change or changes smaller than previously defined in any of the mentioned parameters. 2years
See also
  Status Clinical Trial Phase
Withdrawn NCT06087731 - Efficacy and Safety of Tocilizumab for TAO Phase 2
Recruiting NCT05110040 - Multi-model Image of Immunosuppressive Agents in TAO N/A
Recruiting NCT06112340 - A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Phase 2/Phase 3
Recruiting NCT04548284 - Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO Phase 3
Recruiting NCT03515863 - Natural History and Risk Factors of TAO
Not yet recruiting NCT06392906 - Orbital Radiotherapy in Grave's Ophthalmopathy 1 Week vs 2 Weeks (OraGO-1 Trial) Phase 3
Recruiting NCT06226545 - A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease Phase 2
Completed NCT00150111 - Rituximab in the Treatment of Graves' Disease Phase 1/Phase 2
Completed NCT03110848 - Effects of Atorvastatin in Graves' Orbitopathy (GO) Phase 2
Recruiting NCT04662190 - Evaluation of the Efficacy and Safety of 3D Printing for Orbital Surgery. N/A
Active, not recruiting NCT05276063 - A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Phase 2/Phase 3
Not yet recruiting NCT04919694 - Combination of Orbital Compression Surgery and Strabismus Surgery for Thyroid Associated Ophthalmopathy N/A
Recruiting NCT03131726 - Treatment of Graves´Ophthalmopathy With Simvastatin (GO-S) Phase 3
Completed NCT02766660 - Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy N/A
Active, not recruiting NCT06269393 - A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy Phase 3
Not yet recruiting NCT03098225 - A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy Phase 4
Recruiting NCT05112211 - Multi-model Image of Doxycycline in TAO N/A